Jon Mcclelland Lockard

Array ( [id] => 20795454 [patent_doc_number] => 20260176353 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-06-25 [patent_title] => ANTI-CACFD1 (CALCIUM CHANNEL FLOWER DOMAIN CONTAINING 1) ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 19/431026 [patent_app_country] => US [patent_app_date] => 2025-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42596 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 293 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19431026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20777935 [patent_doc_number] => 20260166128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-06-18 [patent_title] => HUMAN AMYLIN ANALOG, AND DERIVATIVE THEREOF AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/387401 [patent_app_country] => US [patent_app_date] => 2025-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7675 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19387401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20607121 [patent_doc_number] => 12582700 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-24 [patent_title] => Activin receptor type IIA variants and methods of use thereof [patent_app_type] => utility [patent_app_number] => 19/229468 [patent_app_country] => US [patent_app_date] => 2025-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 17 [patent_no_of_words] => 18475 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19229468 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20308065 [patent_doc_number] => 20250325694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-23 [patent_title] => ANTIBODY-OLIGONUCLEOTIDE CONJUGATE COMPOSITIONS AND METHODS OF INDUCING DMD EXON 52 SKIPPING [patent_app_type] => utility [patent_app_number] => 19/097593 [patent_app_country] => US [patent_app_date] => 2025-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32436 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19097593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19754407 [patent_doc_number] => 20250042972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-06 [patent_title] => VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION [patent_app_type] => utility [patent_app_number] => 18/924707 [patent_app_country] => US [patent_app_date] => 2024-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4797 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18924707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19601159 [patent_doc_number] => 20240392039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => ANTI-C5 ANTIBODIES COMBINATIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/797913 [patent_app_country] => US [patent_app_date] => 2024-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19295 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18797913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554933 [patent_doc_number] => 20240366725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE [patent_app_type] => utility [patent_app_number] => 18/784736 [patent_app_country] => US [patent_app_date] => 2024-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8285 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18784736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19816783 [patent_doc_number] => 20250074990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/765952 [patent_app_country] => US [patent_app_date] => 2024-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61657 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18765952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20040908 [patent_doc_number] => 20250179130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-05 [patent_title] => METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS [patent_app_type] => utility [patent_app_number] => 18/749127 [patent_app_country] => US [patent_app_date] => 2024-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18749127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20527298 [patent_doc_number] => 12545722 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-10 [patent_title] => Pharmaceutical compositions targeting immune-mediated processes in neurodegenerative disease [patent_app_type] => utility [patent_app_number] => 18/650019 [patent_app_country] => US [patent_app_date] => 2024-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 148 [patent_figures_cnt] => 160 [patent_no_of_words] => 21248 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18650019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300046 [patent_doc_number] => 20240228615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => ANTI-TREM-1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/621534 [patent_app_country] => US [patent_app_date] => 2024-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18621534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19815099 [patent_doc_number] => 20250073306 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => FORMULA OF NEUREGULIN PREPARATION [patent_app_type] => utility [patent_app_number] => 18/618991 [patent_app_country] => US [patent_app_date] => 2024-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12028 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343626 [patent_doc_number] => 20240252589 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => AGENT FOR ENHANCING PHAGOCYTOSIS ABILITY OF NEUTROPHILS [patent_app_type] => utility [patent_app_number] => 18/595513 [patent_app_country] => US [patent_app_date] => 2024-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5965 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18595513 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318372 [patent_doc_number] => 20240239915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => FC VARIANT WITH HIGH THERMAL STABILITY AND ATTENUATED EFFECTOR FUNCTION [patent_app_type] => utility [patent_app_number] => 18/592409 [patent_app_country] => US [patent_app_date] => 2024-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18592409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19975920 [patent_doc_number] => 12343376 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-01 [patent_title] => Methods for inhibiting diazepam binding protein [patent_app_type] => utility [patent_app_number] => 18/444102 [patent_app_country] => US [patent_app_date] => 2024-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 27 [patent_no_of_words] => 17101 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18444102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111233 [patent_doc_number] => 20240122983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => FLT3L-BASED CHIMERIC PROTEINS [patent_app_type] => utility [patent_app_number] => 18/396206 [patent_app_country] => US [patent_app_date] => 2023-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29085 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18396206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19246842 [patent_doc_number] => 20240197826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => USE OF THE EXTRACELLULAR DOMAIN OF TRANSFERRIN RECEPTOR 2 FOR THE DIAGNOSIS AND TREATMENT OF PRIMARY OR SECONDARY SCLEROSING DISEASES [patent_app_type] => utility [patent_app_number] => 18/534366 [patent_app_country] => US [patent_app_date] => 2023-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18534366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127244 [patent_doc_number] => 20240132597 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => METHODS OF USE OF ANTI-SORTILIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/532382 [patent_app_country] => US [patent_app_date] => 2023-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 107368 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18532382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096491 [patent_doc_number] => 20240115718 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA [patent_app_type] => utility [patent_app_number] => 18/505929 [patent_app_country] => US [patent_app_date] => 2023-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67018 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -151 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18505929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19034228 [patent_doc_number] => 20240084043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => METHODS OF TREATING AN EYE DISORDER [patent_app_type] => utility [patent_app_number] => 18/504723 [patent_app_country] => US [patent_app_date] => 2023-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18504723 [rel_patent_id] =>[rel_patent_doc_number] =>)